Vaughan Nelson Investment Management L.P. Cuts Stock Position in Pfizer Inc. $PFE

Vaughan Nelson Investment Management L.P. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 33.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 58,670 shares of the biopharmaceutical company’s stock after selling 30,000 shares during the quarter. Vaughan Nelson Investment Management L.P.’s holdings in Pfizer were worth $1,461,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Horizon Financial Services LLC boosted its holdings in shares of Pfizer by 174.8% in the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 645 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer during the third quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer in the second quarter valued at about $30,000. Darwin Wealth Management LLC acquired a new stake in Pfizer in the second quarter valued at about $32,000. Finally, True Wealth Design LLC boosted its holdings in Pfizer by 302.5% in the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 974 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PFE. Royal Bank Of Canada began coverage on Pfizer in a research note on Tuesday, February 24th. They set an “underperform” rating and a $25.00 target price for the company. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Guggenheim increased their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Daiwa Securities Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a report on Thursday, February 12th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research report on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.19.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Oncology wins and continued pipeline bets are boosting investor optimism even as Pfizer kept a flat 2026 outlook; investors are focusing on potential upside from new oncology launches and late‑stage programs. Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook
• Positive Sentiment: New real‑world data from a Swedish study on Ibrance (palbociclib) was highlighted by Pfizer — positive evidence could support prescribing confidence and sustain CDK4/6 revenue streams. Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors
• Neutral Sentiment: Market commentary notes Pfizer’s shares rose but still underperformed the broader market — a reminder this move may be sentiment‑driven rather than tied to a clear beat‑through in fundamentals. Pfizer Inc. stock rises Tuesday, still underperforms market
• Neutral Sentiment: Coverage noting heavy retail/institutional interest and index/ETF allocation dynamics (S&P healthcare tracking) — flows and attention can amplify moves but don’t guarantee durable fundamentals. Pfizer Inc. (NYSE:PFE) Tracks Healthcare Allocation In S&P 500 fund
• Neutral Sentiment: Press pieces note shares have risen since Jim Cramer labeled a “pass” — illustrates how media/sentiment narratives around Pfizer’s GLP‑1/weight‑loss program can move the stock independently of near‑term earnings. Pfizer’s (PFE) shares up since Jim Cramer said “Pass”
• Negative Sentiment: Pfizer is exiting its ownership role in the ViiV Healthcare HIV joint venture as GSK and Shionogi reshape stakes; this reduces Pfizer’s exposure to a stable HIV franchise and shifts future upside to partners (though it may generate near‑term cash). GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture Shionogi boosts ViiV Healthcare stake as Pfizer exits joint HIV venture
• Negative Sentiment: Report that Pfizer will close a South San Francisco research site — a potential cost‑saving / restructuring signal that could slow near‑term R&D throughput or reflect portfolio pruning. Pfizer is said to close South San Francisco research site

Pfizer Price Performance

Shares of NYSE:PFE opened at $28.08 on Wednesday. The firm has a market capitalization of $159.67 billion, a price-to-earnings ratio of 20.65 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The business’s 50 day simple moving average is $26.94 and its 200-day simple moving average is $25.75. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $28.31.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the business posted $0.63 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.